EL7.AI
StocksMedium•11 November 2026•
4 min read

NEXGEL Agrees With Holders of 95% of Its Debt to Convert It Into Shares in Recapitalization

Key Facts

1Holders of about 95% of the outstanding note principal signed agreements to convert it into common shares, subject to completion of a merger and other conditions.
2The conversion agreements cover $14.125 million of $14.885 million in outstanding principal debt.
3The financing terms include share purchases at $5.50 per share and warrants covering 100% of those shares, with an exercise price of $10.
4If the merger is not completed by March 31, 2027, subject to a possible extension, the note conversions will not proceed and the notes will remain outstanding.

NEXGEL said in a statement issued on November 11 that holders of about 95% of the outstanding principal of its convertible notes had signed agreements to convert them into common shares. The agreements cover $14.125 million of total principal debt of $14.885 million, according to the company. The conversion remains conditional on completion of a strategic merger and other conditions, so the announcement does not mean the debt has already been canceled. The plan combines conversion of most of the notes with new initial financing, which the company said is intended to support liquidity, transaction costs and immediate operational and strategic work. The stated use of the liquidity is tied to pursuing a potential merger, not to completion of a definitive transaction.

Under the agreement, participating noteholders will receive interest accrued through September 30, 2026, in common shares upon conversion rather than in cash. The company said interest accrued since October 1, 2026, is suspended and will not be due if conversion occurs. These terms set out how interest will be treated as part of the recapitalization, alongside the principal covered by the agreements. The information provided did not specify the number of shares to be issued upon conversion of the principal or interest. The potential change in shareholders’ stakes therefore remains tied to the final conversion terms.

The new financing includes the purchase of common shares at a fixed price of $5.50 per share, with warrants covering 100% of the shares purchased and an exercise price of $10 per share. NEXGEL said the initial financing will provide liquidity for transaction costs and the immediate operational and strategic work needed to pursue the merger. The share purchase price differs from the warrant exercise price under the terms announced by the company. The statement, in the information available, did not specify the amount of the initial financing or the number of shares and warrants involved. The company said additional growth capital may be raised upon completion of the potential merger to support the combined operations, integration and post-transaction growth initiatives.

The company is considering a strategic merger with Fountainhead LifeSciences and its subsidiaries, including Sequence and NVISION Biomedical Technologies, according to its statement. It said the transaction would be with a related party. The company has not announced completion of the merger, describing it instead as under consideration, and linked execution of the note conversions to it. If the merger is not completed by March 31, 2027, subject to a possible extension, the referenced conversions will not proceed and the notes will remain outstanding. In that case, the shares purchased through the new financing will be replaced with convertible notes.

Interim Chief Executive Brian Keiser said NEXGEL had implemented calculated annual savings of about $2.25 million and was pursuing additional savings and reductions in losses from underperforming operations of up to $1.75 million. This effort puts cost reductions among the company’s steps alongside the recapitalization and search for a merger. NEXGEL announced on August 20, 2026, that it had appointed Keiser interim chief executive and formed a special committee to review strategy and value creation. The committee was tasked with reviewing operations, assets, liquidity and strategic direction, and the company said at the time that it expected to prepare an initial framework and present it to the board within 30 to 45 days. The board also identified growth opportunities at the time, including BioNX Surgical, BioNX Regenerative Eye Health & Aesthetics and advanced hydrogel technologies.

On the company’s market position, NEXGEL said on October 27 that it had regained compliance with Nasdaq listing requirements. Its shares closed at $3.65 on November 9, then at $3.58 on November 10, according to EL7 data. The recapitalization statement was announced the following day, November 11. These closing prices place the stock’s movement before the announcement in a clear timeframe, without attributing the price change to the agreements announced later, based on EL7 data. The next step remains tied to the course of the merger review and the deadline set for its completion, which may be extended.

Open on chart